Haukoos, Jason S. http://orcid.org/0000-0001-7784-6811
Rowan, Sarah E.
Galbraith, James W.
Rothman, Richard E.
Hsieh, Yu-Hsiang
Hopkins, Emily
Houk, Rachel A.
Toerper, Matthew F.
Kamis, Kevin F.
Morgan, Jake R.
Linas, Benjamin P.
Al-Tayyib, Alia A.
Gardner, Edward M.
Lyons, Michael S.
Sabel, Allison L.
White, Douglas A. E.
Wyles, David L.
Adler, Amy
Alishahi, Musheng
Avornu, Gideon D.
Becerra, Alexis
Becerra-Ashby, Erika
Bot, Samantha
Boyle, Alexander J.
Bracey, Annetta M.
Breyer, Michael
Camacho, Claudia
Cupelo, Alicia
Dashler, Gaby
Doyle, Pamela
Eicher, Amy
Gardner, Heather
de Gruiter, Carrie Anne
Gravitz, Stephanie
Henry, Sophia
Higgins, David
Hill, Trevor
Johnson, Nyah
Kile, Alex
Liebl, Janet
Lyle, Carolynn
Maliszewski, Barbara
Maliszewski, Kendall
McGoey, Robert
McKenzie, Catherine
Minturn, Matthew S.
Myer, Deanna
Neumann, Kendra
Ossian, Cole
Peacock, Rebekah K.
Perez, Danielle
Pramanick, Tannishtha
Ricketts, Erin P.
Riggan, Benji
Riser, Sherry
Roosevelt, Genie
Saheed, Mustapha
Shy, Bradley
Simpson, Scott
Trest, Gil
Unsworth, Madison
Waltrous, Laura
Watson, Brooke
,
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA042982)
Article History
Received: 14 October 2021
Accepted: 31 March 2022
First Online: 25 April 2022
Declarations
:
: For the Screening Trial and to enhance and streamline the Institutional Review Board (IRB) process, COMIRB, the primary IRB for Denver Health, serves as the central IRB for all sites, including Denver Health, Johns Hopkins University, and the University of Mississippi Medical Center, with the latter two sites ceding to COMIRB. Institutional review board approval was originally granted on December 17, 2017, with a waiver of informed consent.
: Not applicable.
: JSH has received grant funding from the Centers for Disease Control and Prevention (CDC) (R01CE003006). SER has received programmatic funding from Gilead Sciences, Inc. KFK receives salary support via grant funding from Gilead Sciences, Inc. JRM has received grant funding from the National Institute on Drug Abuse (NIDA) (P30DA040500). EMG serves as site principal investigator for clinical trials sponsored by Cepheid, Gilead Science, and Viiv Healthcare. MSL and DAEW receive investigator-initiated grant support paid to the institution from Gilead Sciences. All other authors declare that they have no competing interests.